References
- Goldberg Y, Porat RM, Kedar I, et al. Mutation spectrum in HNPCC in Israeli population. Fam Cancer. 2008;7(4):309–317.
- Weitzel JN, Lagos V, Blazer KR, et al. Prevalence of BRCA mutations and found effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev. 2005;14:1666–1671.
- Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10:705–713.
- Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676–89.
- Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations on BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401–1408.
- Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328–2335.
- Robson M, Svahn T, McCormick B, et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 and BRCA2: A clinic-based series. Cancer. 2005;103:44–51.
- Desai DK, Barkel D. Syndromic colon cancer: Lynch syndrome and familial adenomatous polyposis. Gastroenterol Clin North Am. 2008;37(1):47–72.
- ASCO. American society of clinical oncology policy statement update: Genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397–2406.
- Daly MB, Axibund JE, Bryant E, et al. Genetic/familial high-risk assessment breast and ovarian. J Natl Compr Canc Netw. 2006;4:156–176.
- McKinnon WC, Baty BJ, Bennet RL, et al. Predisposition genetic testing for late onset-disorders in adults. A position paper of the National Society of Genetic Counselors. JAMA. 1997;278:1217–1220.
- U.S. Preventative Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement. Ann Intern Med. 2005;143:355–361.
- Wideroff L, Vadaparampil ST, Breen N, et al. Awareness of genetic testing for increased cancer risk in the year 2000 National Health Interview Survey. Community Genet. 2003;6:147–156.
- Walsh T, Casadei S, Coast KH, et al. Spectrum mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295:1379–1388.
- Zhou XP, Waite KA, Pilarski R, et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Gen. 2003;73:404–411.
- Neumann HPH, Pawlu C, Peczkowska M, et al. Distinct clinical features characterize paraganglioma syndromes associated with SDHB and SDHD mutations. JAMA. 2001;292:943–951.
- Sweet K, Willis J, Zhous XP, et al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA. 2006;294:2465–2473.
- Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol. 2002;20(6):1480–1490.